7even years ago @PNASNews published results of our neuroimaging exploration with #LSD, bravely led daily by @RCarhartHarris and a young trio @LeorRoseman myself and @MendelKaelen in the early days of @Imperial_PRG, exploring unknown frontiers despite huge prejudice all around... One day, with LSD inside my blood, I saw an unforgetable infinitude of things, including the MRI transform into a massive surgical robot laser-cutting thin slices of my brain which flew at light speed into the computer screen in the nearby room...

This equinox the @IPCC_CH released the updated edition of our best "manual for spaceship earth" 😉, nicely summarized by Prof. @KHayhoe here:

https://twitter.com/KHayhoe/status/1637875896433385481?t=-eRtDDqFOSd2hbsaUL81lQ&s=19

Should we build connections between our existential #climatecrisis and psychedelics?
🧵👇 In a nutshell:
"a batata 🥔 ta assando 🔥"
(the potato is roasting), as people say in Brazil 🇧🇷 when facing complicated problems

This is likely the single most important paper in psychedelic science 💫 since "the LSD lid" (2017) and the "dmt-sigma 1" (2009) publications

What connects them is literally mind-blowing 🤯 Absolutely congrats to @DEOlsonLab and all collaborators 👏👏👏👏👏 science.org/doi/10.1126/sc…

This week #psychedelics, almost completely ignored by western science and medicine in the last quarter of the 20th century, made it to the top of 🇺🇸 healthcare, the @NIH:

4k folks 🌐 21 time zones
+10h of talks
Panelists from
🇺🇸 12
🇨🇦 1
🇮🇱 1
🇩🇰 1
🇬🇧 1
🇳🇿 1
🇨🇭 1

🧵 summary 👇 Agenda comprised 3 main themes:
Basic and translational research 🐀🔬👩‍🔬👨‍🔬🧮💻
Clinical trials 👩‍⚕️🧑‍⚕️👨‍⚕️🤮💊🤒💉
Optimising future trial designs 💾💽💿📀

Third and last session of #psychedelics @NIH 🇺🇲 workshop starting now, looking at how to optimize clinical trials design and how to get these treatments approved 🧵 Starting with Ido @hartogsohn 🇮🇱 on psychedelic set and setting theory

Today is the second day of psychedelics @NIH 🇺🇲 with a critical issue to be tackled:

What is a #controlled study with psychedelics?

How to do it?

Why is it important? Starting now with Michael Bogenschutz from @nyuniversity discussing what was left in the background yesterday: subjective effects

Psychedelics making it today to the top of USA 🇺🇲 health institutions: @NIH Joshua Gordon started emphasizing NIH's #mechanistic funding focus

researchgate.net/publication/35…

Overcoming #EpistemicInjustices in the biomedical study of #ayahuasca: Towards #ethical and sustainable #regulation. New paper for “Cultural context and ethical issues in the therapeutic use of psychedelics” special issue of Transcultural Psychiatry 🧵1/ We (me and non-tweeter 🇧🇷 PhD lawyer Konstantin Gerber) reviewed 4 decades of biomedical research about the sacred and ancient vine of the Amazon, documenting how biomedicine systematically commits a specific kind of injustice: against indigenous people as givers of knowledge. 2/

1/16 THREAD🧵3 years ago I proposed that #Psychedelic-Assisted Psychotherapy (PAP) is a #ParadigmShift in psychiatry. The paper has been viewed almost 80k times around the globe and sits at the top 1% views/downloads and top 8% citations of the whole @FrontiersIn journal series. 2/16 Published in the special issue “Psychedelic Drug Research in the 21st Century” it has 82 citations at Google Scholar and was included in one slide by Javier Muñiz, from the FDA’s division of psychiatry, at his ISRP lecture in Oct/2019 frontiersin.org/articles/10.33…

1/18 This tweet completes two months today (and our paper 74 days). What happened since? [a non exhaustive psychedelic patenting thread]

https://twitter.com/ee_schenberg/status/1350116533817798656

2/18 We got close to 6k views (approx 80/day)